Insulin Therapy. What’s New?
The article deals with the need for insulin therapy in patients with diabetes mellitus (DM) type 2. In recent years, the indications for insulin therapy in patients with DM type 2 have increased significantly. According to the UK prospective DM (UKPDS), annually 5–10 % of patients with newly diagnosed DM type 2 require insulin therapy type, and after 10–12 years — 80 % of patients in need of treatment with insulin, which is associated with decreased insulin secretion by β-cells by approximately 4 % per year.
For ease of use and greater patient adherence to insulin therapy in the pharmaceutical market there are presented insulins Insuman® Rapid, Insuman® Basal, Insuman® Comb 25 in disposable injection pen SoloStar. They are the only insulins being released in that form as of today.
Full Text:PDF (Русский)
UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. — 1998. — 352. — 837-853.
UKPDS Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study // BMJ. — 2000. — Vol. 321. — P. 405-412.
Genuth S. A case for blood glucose control // Adv. Int. Med. — 1995. — 40. — 573-623.
Weng J., Li Y. et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial // Lancet. — 2008. — Vol. 371. — P. 1753-1760.
Kaiser P., Maxeiner S. at al. Assessment of the Mixing Efficiency of Neutral Protamine Hagedorn Cartridges // Journal of Diabetes Science and Technology. — 2010. —Vol. 4. —P. 652-657.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2019